EUCTR2012-002338-35-GB进行中（未招募）1 期
ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial) - ATTEST
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 322
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with recurrent paroxysmal AF for at least 2 years, with = 2 episodes over the last 6 months; 2.HATCH Score of at least =1 and = 4 3.Eligible for catheter ablation and for anti-arrhythmic or rate control medications, after having failed at least 1 but no more than 2 prescribed drugs (either anti-arrhythmic or rate control drug). 4.Age 60 years or older. 5.Left Atrium diameter = 55mm by Trans Thoracic Echocardiographie. 6.Left Ventricule ejection fraction = 50% when in sinus rhythm or LV ejection fraction = 35% when in AF. 7.Patient signed the Informed Consent Form and is able and willing to comply with protocol requirements, including all baseline and follow- up testing.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 280
排除标准
- •1.Patients awaiting cardiac transplantation or other cardiac surgery. 2.Acute illness (ongoing) or active systemic infection or sepsis which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant of the study. 3.Reversible causes of AF, e.g. but not limited to thyroid disorders, acute alcohol intoxication, recent major surgical procedures or trauma,… 4.Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months. 5.Heart failure decompensation. 6.Previously diagnosed with persistent/permanent AF/AT 7.Previously required cardioversion >48 hours after onset of AF/AT 8.Subject having previous TIA or stroke (cerebrovascular accident) one year prior to patient enrolment and/or no sufficient recovery. 9.Pulmonary embolism or recent atrial embolism/thrombosis. 10.Hypertrophic obstructive cardiomyopathy. 11.Class IV angina or Class IV CHF (including past or planned heart transplantation). 12.Mandated anti-arrhythmic drug therapy for disease conditions other than AF. 13.Heritable arrhythmias or increased risk for torsade de pointes with class I or III Drugs. 14.Prior LA catheter ablation with the intention of treating AF; prior surgical interventions for AF such as the MAZE procedure. 15.Prior AV nodal ablation. 16.Patients presenting contra-indications for the study catheter(s), as indicated in the respective Instructions For Use. 17.Contraindication to warfarin, other anticoagulation therapy, or all anti-platelet medications. 18.Medical conditions limiting expected survival to < 3 years. 19.Concurrent participation in any other clinical study. 20.Prior history of non-adherence to prescribed drug regimens. 21.Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial
研究者
相似试验
进行中（未招募）
1 期
Atrial Fibrillation Progression TrialAtrial FibrillationEUCTR2012-002338-35-ESBiosense Webster, Inc.255
进行中（未招募）
1 期
Atrial Fibrillation Progression TrialMedDRA version: 16.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2012-002338-35-DEBiosense Webster, Inc.255
进行中（未招募）
1 期
Atrial Fibrillation Progression TrialAtrial FibrillationEUCTR2012-002338-35-IEBiosense Webster, Inc.330
进行中（未招募）
1 期
Atrial Fibrillation Progression TrialAtrial FibrillationEUCTR2012-002338-35-ATBiosense Webster, Inc.330
进行中（未招募）
1 期
Atrial Fibrillation Progression TrialMedDRA version: 16.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2012-002338-35-CZBiosense Webster, Inc.255